ライフサイエンスコーパス: ulcerative colitis

1 ts (16,902 with Crohn's disease, 12,597 with ulcerative colitis).

2 (P = .18 for Crohn's disease and P = .14 for ulcerative colitis).

3 animod in 197 adults with moderate-to-severe ulcerative colitis.

4 e, mostly shared between Crohn's disease and ulcerative colitis.

5 evelopment of colon cancer as found in human ulcerative colitis.

6 se variant in ADCY7 that doubles the risk of ulcerative colitis.

7 section in patients with Crohn's disease and ulcerative colitis.

8 lammatory bowel disease, Crohn's disease and ulcerative colitis.

9 ged 4-17 years who were newly diagnosed with ulcerative colitis.

10 ancer cohort (p=0.0061) compared with active ulcerative colitis.

11 hallmark of the inflammatory bowel disease, ulcerative colitis.

12 th chronic obstructive pulmonary disease and ulcerative colitis.

13 dysfunction that underlies the pathology of ulcerative colitis.

14 r HLA-DRB1*01:03 in both Crohn's disease and ulcerative colitis.

15 and progression of disease in patients with ulcerative colitis.

16 , range 22-67), 6/8 Crohn's disease, and 2/8 ulcerative colitis.

17 h affects the orbit far more frequently than ulcerative colitis.

18 ransplantation and response to Infliximab in ulcerative colitis.

19 gene and linked them with increased risk for ulcerative colitis.

20 arge bowel inflammation that resembles human ulcerative colitis.

21 to identify patients 18 years or older with ulcerative colitis.

22 decreased in patients with colon cancer and ulcerative colitis.

23 d outcomes of adults with moderate-to-severe ulcerative colitis.

24 patients with moderately-to-severely active ulcerative colitis.

25 .1 and interleukin 9 (IL-9) in patients with ulcerative colitis.

26 human patients with Clostridium difficile or ulcerative colitis.

27 in gut mucosa among associations stronger in ulcerative colitis.

28 emission in patients with moderate to severe ulcerative colitis.

29 evalence (69 studies) of Crohn's disease and ulcerative colitis.

30 trials of tofacitinib therapy in adults with ulcerative colitis.

31 mine serves as the gold standard in treating ulcerative colitis.

32 on the risk of colorectal cancer related to ulcerative colitis.

33 ies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

34 3% and 0.7% (odds ratio 1.75; 1.44-2.13) for ulcerative colitis.

35 ransplantation and response to Infliximab in ulcerative colitis.

36 l Modification (ICD-9-CM) diagnosis code for ulcerative colitis.

37 00547659 in patients with moderate to severe ulcerative colitis.

38 vere psoriasis (1.29; 95% CI, 1.12-1.47) and ulcerative colitis (1.26; 95% CI, 1.14-1.40).

39 asis (85 232), bullous skin diseases (4284), ulcerative colitis (12 203), Crohn's disease (7628), inf

40 disease +11.1% [95% CI 4.8-17.8] and APC for ulcerative colitis +14.9% [10.4-19.6]) and Taiwan (APC f

41 ents with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with

42 ne patients out of 100 (Crohn's disease- 67, ulcerative colitis- 23 and IBDU-10) had known TPMT mutat

43 2 per 100 000 in Germany) and North America (ulcerative colitis 286 per 100 000 in the USA; Crohn's d

44 y of patients had Crohn's disease (40.3%) or ulcerative colitis (30.5%).

45 Crohn's disease +4.0% [1.0-7.1] and APC for ulcerative colitis +4.8% [1.8-8.0]).

46 t reported prevalence values were in Europe (ulcerative colitis 505 per 100 000 in Norway; Crohn's di

47 1088 patients with Crohn's disease, 361 with ulcerative colitis, 62 with IBD type unknown, and 1797 c

48 ected in intestinal samples of patients with ulcerative colitis, a condition associated with increase

49 nd their metabolism is often dysregulated in ulcerative colitis, a major category of inflammatory bow

50 Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients rece

51 ween colitis-associated cancer and different ulcerative colitis activity states.

52 onoscopy; 322 were screened by MRC (222 with ulcerative colitis and 100 with Crohn's disease).

53 were present there in 11 of 13 patients with ulcerative colitis and 14 of 15 with Crohn's disease.

54 nflammatory bowel diseases (n = 119; 59 with ulcerative colitis and 60 with Crohn's disease).

55 livered by acute CS had an increased risk of ulcerative colitis and celiac disease, whereas children

56 sregulated in a range of diseases, including ulcerative colitis and colorectal cancer.

57 nflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn disease, are chronic inflam

58 5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disease.

59 Ulcerative colitis and Crohn's disease are the two main

60 Ulcerative colitis and Crohn's disease are the two predo

61 Conventional end points for trials in ulcerative colitis and Crohn's disease have been based o

62 To be included in the systematic review, ulcerative colitis and Crohn's disease needed to be repo

63 lammatory bowel diseases (IBD, which include ulcerative colitis and Crohn's disease) are abdominal pa

64 hitecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the

65 Inflammatory bowel disease includes ulcerative colitis and Crohn's disease.

66 had been admitted, unscheduled, with severe ulcerative colitis and failed to respond to intravenous

67 bitor of MMP9, has shown promise in treating ulcerative colitis and gastric cancer.

68 ch as Crohn disease, multiple sclerosis, and ulcerative colitis and hereby elucidate the molecular me

69 strongest associations were observed between ulcerative colitis and HLA rs9271366 (P = 7.5 x 10(-6)),

70 in human ileal tissues from individuals with ulcerative colitis and intestinal carcinomas, also have

71 In both humans with long-standing ulcerative colitis and mouse models of colitis-associate

72 Ps in IL23R, IL12B, and C2orf43; and between ulcerative colitis and SNPs near HDAC11 and near LINC009

73 reased compared with patients with quiescent ulcerative colitis and that colitis was attenuated in IL

74 They were all diagnosed as ulcerative colitis and treated with mesalazine orally.

75 at will be available include vedolizumab for ulcerative colitis and ustekinumab for Crohn's disease,

76 id arthritis, multiple sclerosis, lupus, and ulcerative colitis) and in some forms of cancer.

77 bowel disease (IBD; i.e. Crohn's disease or ulcerative colitis) and typically developing children wi

78 als with Crohn disease, 149 individuals with ulcerative colitis, and 142 healthy control subjects to

79 Crohn's disease, 19/100,000 person-years for ulcerative colitis, and 5/100,000 person-years for IBD u

80 probiotic activity used in the treatment of ulcerative colitis, and a carcinogenic activity under ho

81 increased susceptibility to Crohn's disease, ulcerative colitis, and asthma.

82 nts with Crohn's disease and 8 patients with ulcerative colitis, and from normal colon of 8 healthy i

83 and compared with other Crohn's phenotypes, ulcerative colitis, and non-Crohn's patients.

84 f recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy.

85 ue therapeutic approach for the treatment of ulcerative colitis, and phase 3 studies have been planne

86 lved in the pathogenesis of Crohn's disease, ulcerative colitis, and pouchitis.

87 arthritis and significantly least similar to ulcerative colitis, and provided support for three addit

88 relapse in patients with Crohn's disease or ulcerative colitis (approximately 75% of patients experi

89 Crohn's disease, ileal Crohn's disease, and ulcerative colitis are all genetically distinct from eac

90 Crohn's disease and ulcerative colitis are heterogeneous inflammatory bowel

91 Celiac disease, Crohn disease and ulcerative colitis are inflammatory disorders of the gas

92 Crohn's disease and ulcerative colitis are the primary inflammatory bowel di

93 Crohn's disease and ulcerative colitis are the two major forms of inflammato

94 el diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relapsing conditions tha

95 erative colitis) than by Crohn's disease and ulcerative colitis as currently defined.

96 e associated orbital myositis and 3 cases of ulcerative colitis associated orbital myositis have been

97 T3 pathway plays a crucial role in promoting ulcerative colitis-associated carcinoma (UCC).

98 tients undergoing colonoscopic screening for ulcerative colitis at the Leicester General Hospital, Le

99 tor cells, including pathogenic TH2 cells in ulcerative colitis, but is expressed poorly or not at al

100 of similar efficacy in treating acute severe ulcerative colitis, but there has been no comparative ev

101 tiating profiles between Crohn's disease and ulcerative colitis by means of (orthogonal) partial leas

102 T cells serves an important role in driving ulcerative colitis by regulating intestinal epithelial c

103 ative regulator of innate immunity) in human ulcerative colitis, by comparing monozygotic twins and o

104 In contrast, ulcerative colitis causes an interstitial lymphocytic an

105 atures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Cr

106 uced colitis and human colonic biopsies from ulcerative colitis, compared with controls.

107 ively, who had moderately to severely active ulcerative colitis despite previous conventional therapy

108 -naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who re

109 g obesity, atherosclerosis, Crohn's disease, ulcerative colitis, drug toxicity, and even autism.

110 Mayo Clinic endoscopic subscores (MCSe) and ulcerative colitis endoscopic index of severity (UCEIS)

111 on carcinogenesis and in human patients with ulcerative colitis, even in tissue that appears histolog

112 ontaneous production of cytokines from human ulcerative colitis explants.

113 Intestinal tissues from patients with ulcerative colitis expressed significantly lower levels

114 ries, with a history (>/=3 months) of active ulcerative colitis extending more than 15 cm beyond the

115 een achieved and the patient is remission of ulcerative colitis for the last six months.

116 ncidence or prevalence of Crohn's disease or ulcerative colitis from 1990 or later.

117 sk estimates of colorectal cancer related to ulcerative colitis from Asia vary.

118 se for terms related to colorectal cancer in ulcerative colitis from inception to July 1, 2016.

119 ts (19,713 with Crohn's disease, 14,683 with ulcerative colitis) genotyped on the Immunochip array.

120 Conversely, patients with ulcerative colitis had an increased risk of liver diseas

121 from patients with CD and from patients with ulcerative colitis had distinct changes in DNA methylati

122 reating individuals with Crohn's disease and ulcerative colitis have a growing armamentarium of optio

123 Previous retrospective studies of paediatric ulcerative colitis have had limited ability to describe

124 d risk of surgery, while former smokers with ulcerative colitis have increased risk of colectomy.

125 Patients with ulcerative colitis have mucosal inflammation starting in

126 surgery in patients with Crohn's disease and ulcerative colitis have reached inconsistent conclusions

127 diseases (IBD) known as Crohn's disease and ulcerative colitis have shown strong evidence of associa

128 s disease (hazard ratio 2.19; 1.44-3.34) and ulcerative colitis (hazard ratio 1.63; 1.18-2.27) was si

129 efficacy in patients with moderate-to-severe ulcerative colitis; however, complex factors determine t

130 of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that expression correlat

131 potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.

132 against the development of Crohn disease and ulcerative colitis in humans.

133 ion of mucosal integrity, and contributes to ulcerative colitis in mice and humans.

134 follow-up, 48 men were newly diagnosed with ulcerative colitis (incidence rate (IR) = 36/100,000 per

135 Treatments for ulcerative colitis include 5-aminosalicylic acid drugs,

136 ammatory bowel diseases (IBDs), particularly ulcerative colitis, intestinal macrophages (MPhis), eosi

137 ADT was associated with a decreased risk of ulcerative colitis (IR = 24/100,000 PY vs. IR = 50/100,0

138 Ulcerative colitis is a chronic inflammatory disease aff

139 Ulcerative colitis is an established risk factor for col

140 The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs

141 The patient of ulcerative colitis is increasing every year and it is an

142 nditions in patients with Crohn's disease or ulcerative colitis is necessary for their total care and

143 m is not understood, and the role of Nod2 in ulcerative colitis is not known.

144 The increased risk of colorectal cancer in ulcerative colitis is well known.

145 l disease (IBD), including Crohn disease and ulcerative colitis, is characterized by chronic intestin

146 anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcome

147 Australia (23 with Crohn's colitis, 29 with ulcerative colitis; median age, 45.0 y; 60% male; mean I

148 dian age 14.1 years; Crohn's disease n = 22, ulcerative colitis n = 26, unclassified colitis n = 11)

149 eases with >/= 50 validated cases, including ulcerative colitis (n = 151), Crohn's disease (n = 96),

150 ens from the terminal ileum of patients with ulcerative colitis (n = 20), CD (n = 20), or individuals

151 colon tissues from age-matched patients with ulcerative colitis (n=10) vs without IBD (n=8, controls)

152 ease [n = 356] or the partial Mayo score for ulcerative colitis [n = 253]).

153 ents were allocated to three disease groups (ulcerative colitis, n=37; dysplasia, n=2; colitis-associ

154 solated from fecal samples of a patient with ulcerative colitis on the basis of their ability to caus

155 rhea (ICD) in rhesus macaques also resembles ulcerative colitis, one form of human inflammatory bowel

156 nic ILC3 from patients with mild to moderate ulcerative colitis or Crohn's disease had increased IL-2

157 onic tissues from human subjects with active ulcerative colitis or Crohn's disease, implicating the l

158 atients with Inflammatory Bowel Disease like ulcerative colitis or Crohn's disease.

159 lead to inflammatory bowel diseases such as ulcerative colitis or Crohn's disease.

160 ith CD, whereas 12 patients had a history of ulcerative colitis or were strongly suspected of CD base

161 or histological features of Crohn's disease, ulcerative colitis, or IBD unclassified.

162 ears old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24,543.0 pa

163 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bowel disease unclas

164 strong colonic expression, protects against ulcerative colitis (overall P=6.89 x 10(-7), odds ratio=

165 ated macular degeneration (P=1.4 x 10(-12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P

166 Thirty patients (15 Crohns disease, 15 ulcerative colitis) participated, and 92 segmental pairs

167 nt (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up

168 B1, 2/6 Crohn's disease patients are B2, 2/2 ulcerative colitis patients are S2.

169 Macrophages from controls and ulcerative colitis patients carrying the IBD-risk rs1075

170 Fecal supernatants from ulcerative colitis patients induced permeability in the

171 ct from gut microbiota collected from either ulcerative colitis patients or healthy controls, with di

172 nd PAR2(-/-) mice by fecal supernatants from ulcerative colitis patients was assessed.

173 ll-characterized large-duct PSC patients, 96 ulcerative colitis patients, and 100 healthy controls.

174 ression was increased in tissue samples from ulcerative colitis patients.

175 tissues from healthy subjects, patients with ulcerative colitis, patients with celiac disease, and pa

176 golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimum

177 mmatory diseases such as Crohn disease (CD), ulcerative colitis, psoriasis, and type 1 diabetes.

178 e curve (AUC) of scores from the Crohn's and Ulcerative Colitis Questionnaire (CUCQ) completed by par

179 outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib, although at an

180 outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib.

181 icular disease, benign colonic neoplasm, and ulcerative colitis/regional enteritis were included.

182 tic architecture of Crohn's disease (CD) and ulcerative colitis remain incompletely defined.

183 hn's disease and 15 (83.3%) of 18 studies on ulcerative colitis reported stable or decreasing inciden

184 leted golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investi

185 tween PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease

186 heimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabete

187 Finally, in patients with ulcerative colitis, SGPP2 expression was elevated in col

188 ls, models of neurodegenerative diseases and ulcerative colitis suggest the likelihood of this scenar

189 iants and heterozygous advantage observed in ulcerative colitis, suggesting an important role of the

190 The only study in patients with ulcerative colitis supported continued immunomodulator u

191 sease, Hashimoto thyroiditis, Crohn disease, ulcerative colitis, systemic lupus erythematosus, antiph

192 lightly higher rate of clinical remission of ulcerative colitis than placebo.

193 rohn's disease, colonic Crohn's disease, and ulcerative colitis) than by Crohn's disease and ulcerati

194 liac disease, multiple sclerosis, lupus, and ulcerative colitis), the GWAS association arises from mu

195 estigated to delineate mechanisms regulating ulcerative colitis, the role of acid ceramidase (AC) in

196 In patients with ulcerative colitis, there was no difference in the need

197 soriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the rel

198 he response of children newly diagnosed with ulcerative colitis to standardised initial therapy and i

199 the risk of relapse, to discriminate CD from ulcerative colitis, to select candidates to anti-tumor n

200 patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as in

201 We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess re

202 ide genetic correlation (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly gr

203 was associated with Crohn's disease (CD) and ulcerative colitis (UC) among Moroccan patients, and eva

204 The studies included 67,057 patients with ulcerative colitis (UC) and 75,971 patients with Crohn's

205 tic approaches fail to differentiate between ulcerative colitis (UC) and Crohn's colitis (CC) in one-

206 The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

207 AIMS: The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause s

208 In control, ulcerative colitis (UC) and Crohn's disease (CD) groups

209 al tract of uncertain origin, which includes ulcerative colitis (UC) and Crohn's disease (CD).

210 ined from patients with PSC with and without ulcerative colitis (UC) and explanted PSC livers.

211 to determine LP macrophage phenotypes in CD, ulcerative colitis (UC) and healthy controls (HC), and i

212 ase (PIBD), comprising Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease u

213 ulate inflammation during the development of ulcerative colitis (UC) and progression to colitis-assoc

214 owel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) and to compare the occurrence of

215 re to define incident cases of Crohn's (CD), ulcerative colitis (UC) and undifferentiated IBD (IBDU).

216 Crohn disease (CD) and ulcerative colitis (UC) are 2 common inflammatory bowel

217 Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel d

218 Ulcerative colitis (UC) belongs to inflammatory bowel di

219 the mainstay treatments in the management of ulcerative colitis (UC) but up to a third of patients wi

220 Ulcerative colitis (UC) can be treated with surgery or m

221 hnique used to measure endoscopic healing in ulcerative colitis (UC) clinical trials.

222 It is not clear why some patients with ulcerative colitis (UC) do not respond to treatment with

223 The medical management of ulcerative colitis (UC) has improved through the develop

224 The genetic analysis of ulcerative colitis (UC) has provided new insights into t

225 hioprine therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previous

226 hat affect risk for Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients

227 rrelated with development and progression of ulcerative colitis (UC) in human patients.

228 Ulcerative colitis (UC) is a chronic, inflammatory bowel

229 Ulcerative colitis (UC) is a chronic, relapsing and debi

230 Ulcerative colitis (UC) is difficult to treat, and stand

231 Diarrhea associated with ulcerative colitis (UC) occurs primarily as a result of

232 The odds of having ulcerative colitis (UC) or Crohn disease (CD) were eleva

233 ospective study with Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integri

234 ndrome (IBS) is more common in patients with ulcerative colitis (UC) than expected.

235 mmon long-term complication in patients with ulcerative colitis (UC) undergoing proctocolectomy with

236 r role in pediatric Crohn's disease (CD) and ulcerative colitis (UC) we obtained mucosal biopsies of

237 and TJP1) and IBD, Crohn's disease (CD), or ulcerative colitis (UC) were investigated.

238 y bowel diseases (IBD; Crohn's disease (CD), ulcerative colitis (UC)).

239 cting the colon such as medically refractory ulcerative colitis (UC), aggressive Crohn's disease (CD)

240 ve pediatric patients with CD, patients with ulcerative colitis (UC), and control individuals.

241 , colorectal cancer (CRC), benign neoplasms, ulcerative colitis (UC), and Crohn's disease (CD) betwee

242 main forms of irritable bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

243 The ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to dise

244 es (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammator

245 IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC), has been considered a problem i

246 adherence to medication has been noticed for ulcerative colitis (UC), little is known about adherence

247 In both Crohn's disease (CD) and ulcerative colitis (UC), the gut is massively infiltrate

248 Human ulcerative colitis (UC), UC-associated CRC, and sporadic

249 transabdominal minimal invasive approach in ulcerative colitis (UC), using the comprehensive complic

250 ype 2 immune response in the pathogenesis of ulcerative colitis (UC)-few data are available from trea

251 osal inflammatory cytokines in patients with ulcerative colitis (UC).

252 in patients with moderate to severely active ulcerative colitis (UC).

253 (CD) and for 8 SNPs in 5 genes of paediatric ulcerative colitis (UC).

254 al role of Escherichia coli in the course of ulcerative colitis (UC).

255 r been adequately evaluated in patients with ulcerative colitis (UC).

256 nosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC).

257 both in healthy mice and in a mouse model of ulcerative colitis (UC).

258 owel diseases (IBDs): Crohn disease (CD) and ulcerative colitis (UC).

259 f fecal microbiota transplantation (FMT) for ulcerative colitis (UC).

260 thelial barrier defenses are associated with ulcerative colitis (UC).

261 ed in patients with Crohn's disease (CD) and ulcerative colitis (UC).

262 sponse and remission in patients with active ulcerative colitis (UC).

263 al pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (UC).

264 ating patients with Crohn's disease (CD) and ulcerative colitis (UC).

265 ression and function during human and murine ulcerative colitis (UC).

266 se (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).

267 ging treatment options for the management of ulcerative colitis (UC).

268 emission in patients with moderate to severe ulcerative colitis (UC).

269 P70) induction in the colon of patients with ulcerative colitis (UC).

270 e diagnosed as having Crohn disease (CD) and ulcerative colitis (UC).

271 signalling pathway has been associated with ulcerative colitis (UC).

272 nastomosis (IRA) failure after colectomy for ulcerative colitis (UC).

273 ving pathways) contribute to pathogenesis of ulcerative colitis (UC).

274 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (UC); Odds Ratio 1.09, 95 % Confidenc

275 n disease-subtypes, Crohn's disease (CD) and ulcerative colitis (UC); these subtypes share overlappin

276 nts [123 with Crohn disease (CD) and 94 with ulcerative colitis (UC)] were analyzed; 75 of 150 (50%)

277 om patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without

278 matory bowel disease (Crohn disease [CD] and ulcerative colitis [UC]) and diabetic nephropathy (macro

279 tory bowel disease (IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inversely related to typ

280 h IBD (43 with Crohn's disease [CD], 23 with ulcerative colitis [UC]), and 30 children without IBD (c

281 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD];

282 roscopy in 110 consecutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], a

283 Ulcerative colitis usually presents with bloody diarrhoe

284 found no difference between individuals with ulcerative colitis vs Crohn's disease.

285 A 37-year-old man with ulcerative colitis was admitted to the hospital because

286 of IL19 in biopsies of patients with active ulcerative colitis was increased compared with patients

287 of colorectal cancer in Asian patients with ulcerative colitis was similar to recent estimates in Eu

288 HRs for children <6 years old with ulcerative colitis were 0.88 for female patients (95% CI

289 Former smokers with ulcerative colitis were at increased risk of colectomy (

290 variate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of

291 e genes were also activated in patients with ulcerative colitis where chronic inflammation predispose

292 "future" cancer progression in patients with ulcerative colitis who did and did not develop colon can

293 patients with moderately-to-severely active ulcerative colitis who had not responded to conventional

294 patients with moderately-to-severely active ulcerative colitis who participated in ACT-1 or ACT-2; e

295 Crohn's disease and 33 patients with active ulcerative colitis who were candidates to receive inflix

296 R, $87335-$126541]), and total colectomy for ulcerative colitis (WIQR, $24497; median, $34910 [IQR, $

297 miRNA signature identified in mice predicted ulcerative colitis with 83.3% accuracy.

298 sis included a total of 31 287 patients with ulcerative colitis with a total of 293 reported colorect

299 In the treatment of ulcerative colitis with mesalazine, we should pay attent

300 This case report presents a patient with ulcerative colitis, with thrombotic complication of the